microRNAs and Soft Tissue Sarcomas
microRNAs and Soft Tissue Sarcomas
复制标题
microRNA 和软组织肉瘤
DOI：
10.1007/978-3-319-23730-5_10
复制
发表时间：
2015
期刊：
影响因子：
--
通讯作者：
Ozaki T.
中科院分区：
文献类型：
--
作者：
Fujiwara T;Kunisada T;Takeda K;Ozaki T.
软组织肉瘤是一组高度异质性的恶性肿瘤，起源于间质组织，包括肌肉、脂肪和纤维组织、血管和外周神经。目前的诊断方法识别的各种组织学亚型提出了诊断挑战，因为它们的临床和组织病理学特征并不总是不同的。重要的临床问题之一是缺乏有用的生物标志物;因此，发现可用于检测肿瘤或预测肿瘤对化疗或放疗的反应的生物标志物可以帮助临床医生提供更有效的临床管理。最近关于软组织肉瘤中微小RNA（miRNA）的报道为解决这一问题提供了线索。肿瘤组织中的miRNA以及患者血液中的循环miRNA的证据正在加速改变临床应用的潜力。在本章中，我们总结了肿瘤组织和患者血液中失调的miRNAs的新证据，并讨论了miRNAs作为新的生物标志物和治疗靶点的潜力。
Soft tissue sarcomas are a highly heterogenous group of malignant tumors that originate from mesenchymal tissues including muscle, adipose and fibrous tissues, blood vessels, and peripheral nerves. A large variety of histological subtypes that current diagnostic approaches recognize present a diagnostic challenge because their clinical and histopathological characteristics are not always distinct. One of the important clinical problems is a lack of useful biomarkers; therefore, the discovery of biomarkers that can be used to detect tumors or predict tumor response to chemotherapy or radiotherapy could help clinicians provide more effective clinical management. Recent reports on microRNAs (miRNAs) in soft tissue sarcomas have provided clues to solve the problem. Evidence for miRNAs in tumor tissues as well as circulating miRNAs in patients’ blood is accelerating the potential to transform clinical applications. In this chapter, we summarize the emerging evidence of dysregulated miRNAs in tumor tissues and patients’ blood and discuss the potential of miRNAs as novel biomarkers and therapeutic targets.